Horizon Investments LLC Lowers Stake in Pfizer Inc. $PFE

Key Points

• Horizon Investments cut its stake in Pfizer by 75.8% in Q4, selling 590,163 shares and retaining 187,934 shares worth $4.603 million.
• Pfizer beat Q4 estimates with $0.66 EPS vs. $0.57 expected and $17.56 billion in revenue (vs. $16.93 billion), although revenue was down 1.2% year‑over‑year.
• Positive developments — FDA approval for a Pfizer–Arvinas breast cancer therapy, Vyndamax patent settlements extending exclusivity to 2031, and a late‑stage win for Elrexfio — boost medium‑term revenue visibility; Pfizer also announced a $0.43 quarterly dividend (6.5% yield) while analysts remain mixed with a consensus "Hold" and $28.74 target.

Horizon Investments LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 75.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 187,934 shares of the biopharmaceutical company's stock after selling 590,163 shares during the period. Horizon Investments LLC's holdings in Pfizer were worth $4,603,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Triad Wealth Partners LLC lifted its holdings in Pfizer by 1.9% during the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company's stock worth $510,000 after buying an additional 386 shares in the last quarter. ETF Store Inc. lifted its holdings in Pfizer by 3.8% during the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company's stock worth $272,000 after buying an additional 396 shares in the last quarter. Mattern Wealth Management LLC lifted its holdings in Pfizer by 4.6% during the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company's stock worth $228,000 after buying an additional 400 shares in the last quarter. Quest Investment Management LLC lifted its holdings in Pfizer by 1.3% during the 3rd quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company's stock worth $809,000 after buying an additional 405 shares in the last quarter. Finally, Community Bank & Trust Waco Texas lifted its holdings in Pfizer by 0.6% during the 3rd quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company's stock worth $1,703,000 after buying an additional 412 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

Shares of NYSE:PFE opened at $26.35 on Monday. The company's fifty day moving average price is $27.17 and its 200 day moving average price is $26.11. Pfizer Inc. has a 12 month low of $21.97 and a 12 month high of $28.75. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The firm has a market capitalization of $149.80 billion, a P/E ratio of 19.37 and a beta of 0.35.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same period last year, the business earned $0.63 EPS. Pfizer's revenue for the quarter was down 1.2% compared to the same quarter last year. As a group, sell-side analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.5%. The ex-dividend date is Friday, May 8th. Pfizer's dividend payout ratio (DPR) is currently 126.47%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on PFE shares. Argus upgraded shares of Pfizer from a "hold" rating to a "buy" rating and set a $35.00 target price on the stock in a report on Monday, March 2nd. Guggenheim increased their target price on shares of Pfizer from $35.00 to $36.00 and gave the stock a "buy" rating in a report on Tuesday, March 24th. Barclays started coverage on shares of Pfizer in a report on Thursday, February 19th. They set an "underweight" rating and a $25.00 target price on the stock. Cantor Fitzgerald reiterated a "neutral" rating and set a $27.00 target price on shares of Pfizer in a report on Wednesday, February 4th. Finally, Morgan Stanley increased their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock an "equal weight" rating in a report on Friday, April 10th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Pfizer currently has an average rating of "Hold" and a consensus price target of $28.74.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA approval for a Pfizer–Arvinas breast cancer therapy — The U.S. FDA approved the co‑developed drug for a breast cancer indication, giving Pfizer an additional commercial launch and validating its oncology partnership pipeline. This approval creates a new near‑ and medium‑term revenue opportunity and reduces development risk for the asset. US FDA approves Pfizer, Arvinas' breast cancer drug
• Positive Sentiment: Vyndamax patent settlements extend exclusivity to 2031 — Pfizer reached settlements with multiple generic filers that effectively push back generic entry for Vyndamax (tafamidis), protecting a meaningful revenue stream and reducing downside risk from near‑term generic competition. That supports cash flow visibility into the next decade. Pfizer Reaches Settlement to Extend VYNDAMAX Patent Protection Until 2031
• Positive Sentiment: Late‑stage win for multiple myeloma drug Elrexfio — Pfizer reported a late‑stage trial success for Elrexfio, which could expand its oncology franchise and add future revenue streams if regulatory filings follow. Clinical wins can meaningfully re‑rate biotech exposure over time. Pfizer posts late-stage trial win for multiple myeloma therapy Elrexfio
• Positive Sentiment: PADCEV supplemental BLA accepted for priority review — Pfizer (with Astellas) secured FDA acceptance of a PADCEV sBLA for a new use, which could expand indications and sales if approved. This is another program that supports medium‑term growth optionality. Pfizer Among Best Medical Stocks Under $30 to Invest In?
• Neutral Sentiment: Q1 earnings and guidance in focus (May 5) — Wall Street is watching first‑quarter results and guidance; Zacks and other outlets highlight consensus estimates and key revenue/margin line items, with traders positioning ahead of potential beats and for commentary on obesity and specialty drug performance. Earnings will likely be the short‑term catalyst for direction. Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q1 Earnings
• Negative Sentiment: Analyst caution and price‑target cuts are weighing on sentiment — Goldman reportedly trimmed its target and some sell‑side commentary highlights growth concerns despite the patent wins; Morgan Stanley reiterated Equal Weight and flagged patent/growth uncertainty. That cautious analyst tone can sap momentum and contribute to intraday selling. Pfizer Stock Opinions on Vyndamax Settlements and Earnings Outlook Morgan Stanley Maintains Pfizer at Equal Weight

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.